Table 1.
Comparison of baseline physical data between CO and PPO groups
| CO (n = 122) | PPO (n = 183) | p value | |
|---|---|---|---|
| Age, years | 42.2±9.4 | 50.5±10.3 | 0.000* |
| Male, % | 45.9 | 42.1 | 0.509 |
| Body weight, kg | 125.3±31.4 | 114.2±26.7 | 0.002* |
| BMI, kg/m2 | 43.8 (38.6–50.6) | 40.3 (36.7–45.7) | 0.000* |
| FPG, mg/dL | 109.0 (98.0–128.8) | 115.5 (102.0–139.3) | 0.054 |
| HbA1c, % | 6.2 (5.5–7.3) | 6.7 (5.9–8.2) | 0.023* |
| TC, mg/dL | 195.4±45.5 | 204.0±38.9 | 0.212 |
| TG, mg/dL | 138.0 (98.0–205.0) | 160.0 (104.0–218.0) | 0.276 |
| HDL-C, mg/dL | 44.0 (37.5–50.5) | 46.0 (41.0–55.0) | 0.013* |
| Serum creatinine, mg/dL | 0.61 (0.55–0.75) | 0.69 (0.58–0.85) | 0.052 |
| Uric acid, mg/dL | 6.6±1.6 | 6.3±1.6 | 0.332 |
| SBP, mmHg | 140.2±20.0 | 139.5±19.9 | 0.870 |
| DBP, mmHg | 89.3±19.2 | 85.7±13.0 | 0.255 |
| CPR index | 2.9 (2.2–4.2) | 2.7 (2.0–3.6) | 0.068 |
| HOMA-IR | 4.2 (3.1–7.9) | 4.5 (3.0–7.7) | 0.782 |
| HOMA-β, % | 155.3 (66.5–263.3) | 93.9 (60.6–148.1) | 0.023* |
| VFA, cm2 | 163.2 (133.5–208.8) | 198.0 (165.0–244.7) | 0.000* |
| SFA, cm2 | 567.0 (434.4–658.9) | 483.3 (430.0–588.6) | 0.008* |
| VFA/SFA ratio | 0.37±0.20 | 0.48±0.23 | 0.000* |
| Rate of diabetes, % | 60.7 | 67.2 | 0.241 |
| Rate of hypertension, % | 73.7 | 81.8 | 0.098 |
| Rate of dyslipidemia, % | 98.4 | 95.1 | 0.132 |
| Antidiabetic drugs, n | 1 (0–2) | 1 (0–2) | 0.477 |
| Insulin use, % | 4.1 | 9.8 | 0.115 |
| Antihypertensive drugs, n | 0 (0–1) | 1 (0–2) | 0.004* |
| Lipid-lowering drugs, n | 0 (0–1) | 0 (0–1) | 0.439 |
| Rate of OSAS, % | 68.9 | 75.4 | 0.209 |
Data are presented as mean±SD or median (interquartile range) or percentage. CO, childhood onset obesity; PPO, post-puberty onset obesity; BMI, body mass index; FPG; fasting plasma glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; CPR, connecting peptide immunoreactivity; HOMA-IR, homeostasis model assessment (HOMA)-insulin resistance; HOMA-β, HOMA for beta cell function; VFA, visceral fat area; SFA, subcutaneous fat area; OSAS, obstructive sleep apnea syndrome; SD, standard deviation.
*
p value ≤0.05.